id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2015-N-3326-0045,FDA,FDA-2015-N-3326,Reauthorization of the Biosimilar User Fee Act; Public Meeting; Request for Comments,Notice,Request for Comments,2025-11-24T05:00:00Z,2025,11,2025-11-24T05:00:00Z,2026-01-03T04:59:59Z,2026-01-03T13:15:26Z,2025-20654,0,0,09000064b9093657